217 related articles for article (PubMed ID: 26238304)
1. Gene expression in prolactinomas: a systematic review.
Seltzer J; Scotton TC; Kang K; Zada G; Carmichael JD
Pituitary; 2016 Feb; 19(1):93-104. PubMed ID: 26238304
[TBL] [Abstract][Full Text] [Related]
2. Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature.
Seltzer J; Ashton CE; Scotton TC; Pangal D; Carmichael JD; Zada G
Neurosurg Focus; 2015 Feb; 38(2):E17. PubMed ID: 25639319
[TBL] [Abstract][Full Text] [Related]
3. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
4. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas.
Finelli P; Pierantoni GM; Giardino D; Losa M; Rodeschini O; Fedele M; Valtorta E; Mortini P; Croce CM; Larizza L; Fusco A
Cancer Res; 2002 Apr; 62(8):2398-405. PubMed ID: 11956103
[TBL] [Abstract][Full Text] [Related]
5. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
6. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
7. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
Li N; Jiang Z
Clin Neurol Neurosurg; 2017 Feb; 153():102-106. PubMed ID: 28110235
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses.
Evans CO; Moreno CS; Zhan X; McCabe MT; Vertino PM; Desiderio DM; Oyesiku NM
Pituitary; 2008; 11(3):231-45. PubMed ID: 18183490
[TBL] [Abstract][Full Text] [Related]
9. [Differential expression analysis of prolactinoma-related microRNAs].
Chen YX; Li Q; Wang CD; Su ZP; Li WQ; Chen XB; Wu ZB
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(5):320-3. PubMed ID: 22490835
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in the development of prolactinoma in mice overexpressing hCGβ: role of TGFβ1.
Faraoni EY; Camilletti MA; Abeledo-Machado A; Ratner LD; De Fino F; Huhtaniemi I; Rulli SB; Díaz-Torga G
J Endocrinol; 2017 Mar; 232(3):535-546. PubMed ID: 28096433
[TBL] [Abstract][Full Text] [Related]
11. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.
Jiang XB; Hu B; He DS; Mao ZG; Wang X; Song BB; Zhu YH; Wang HJ
BMC Cancer; 2015 Sep; 15():644. PubMed ID: 26400193
[TBL] [Abstract][Full Text] [Related]
13. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
14. MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas.
Xiao Z; Wang Z; Hu B; Mao Z; Zhu D; Feng Y; Zhu Y
Biochem Biophys Res Commun; 2019 Nov; 520(1):79-85. PubMed ID: 31582213
[TBL] [Abstract][Full Text] [Related]
15. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
16. ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.
Liu X; Kano M; Araki T; Cooper O; Fukuoka H; Tone Y; Tone M; Melmed S
Endocrinology; 2015 Jan; 156(1):71-9. PubMed ID: 25375038
[TBL] [Abstract][Full Text] [Related]
17. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma.
Miao Y; Li C; Guo J; Wang H; Gong L; Xie W; Zhang Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1022. PubMed ID: 31692290
[TBL] [Abstract][Full Text] [Related]
19. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression.
Pellegrini-Bouiller I; Morange-Ramos I; Barlier A; Gunz G; Figarella-Branger D; Cortet-Rudelli C; Grisoli F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1996 Sep; 81(9):3390-6. PubMed ID: 8784102
[TBL] [Abstract][Full Text] [Related]
20. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]